Navigation Links
Spectros Signs New International Distribution Deals
Date:10/19/2009

PORTOLA VALLEY, Calif., Oct. 19 /PRNewswire/ -- Spectros, developer and manufacturer of advanced molecular sensing and imaging devices which shed light on life-threatening diseases, announced today that it has signed exclusive distribution deals for both its T-Stat® VLS Tissue Oximeter and Sensors. The markets covered include Australia, New Zealand, The Netherlands, Belgium, Luxembourg (Benelux), Suriname, Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia. The values of the deals were not disclosed.

Founded in 1995, Spectros develops tissue oximeters and sensors for various uses with applications in critical care, gastroenterology, colon-rectal surgery, plastic surgery, and vascular surgery. T-Stat® VLS Tissue Oximeter is an FDA-approved and CE Marking device approved for neonatal, pediatric, and adult use.

"We are proud to be working with our new partners, Endovations in Australia, Fysicon Medical Technology in the Netherlands, and A.M.I. Italia s.r.l. in Italy, who are providing the T-Stat® franchise in their respective markets in order to realize our potential," said David Benaron, CEO of Spectros. "Support of our technology is a testament to their commitment to offering their healthcare communities with innovative and life-saving solutions," commented Robert Kum, director of commercial development.

The T-Stat® franchise includes the T-Stat® VLS Tissue Oximeter, utilizing Visible Light Spectroscopy (VLS), a multi-wavelength, noninvasive, continuous, real-time monitor of absolute hemoglobin oxygen saturation. The T-Stat® Sensors allow for ischemia monitoring in various applications, including critical care (neonatal, pediatric, and adult), gastroenterology (G.I. ischemia diagnosis), colon-rectal surgery (anastomosis), plastic surgery (free flaps), and vascular surgery (AAA, TAAA, and EVAR).

Based in Australia, Endovations Pty. Ltd. is a leader in the field of critical care, respiratory, anesthesia, and surgical applications. Endovations will distributor the T-Stat® VLS Tissue Oximeter and Sensors to the Australian and New Zealand markets.

Based in the Netherlands, Fysicon Medical Technology is a leader in the field of cardiology. The company will distribute the T-Stat® VLS Tissue Oximeter and Sensors to the Dutch, Belgium, and Luxembourgian (Benelux), and Suriname markets.

Based in Italy, A.M.I. Italia s.r.l. is a leader in the patient monitoring market. A.M.I. will distribute the T-Stat® VLS Tissue Oximeter and Sensors in Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia.

About Spectros

Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, non-invasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy. Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally. For further information, contact Elizabeth van Thillo, Marketing, Spectros Corporation, at info@spectros.com or 650/529.2865

SOURCE Spectros


'/>"/>
SOURCE Spectros
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Europes number 1 scientific network signs off with launch of new report
2. Kings College London signs agreement to strengthen Brazilian research links
3. New DNA test uses nanotechnology to find early signs of cancer
4. University has grand designs to build a house of straw
5. Web-based program designs more efficient farm terrace layouts
6. WARF signs license agreement with Pfizer for human embryonic stem cells
7. Unifying the animate and the inanimate designs of nature
8. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
9. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
10. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
11. Engineering technology pinpoints earliest signs of animal life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: